SUPERNUS PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Supernus Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2011 to Q3 2024.
  • Supernus Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $40.8M, a 402% increase year-over-year.
  • Supernus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was $46.1M, a 46.4% decline from 2021.
  • Supernus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was $86M, a 50.5% decline from 2020.
  • Supernus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2020 was $174M, a 16.9% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $40.8M +$32.7M +402% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $22.6M +$40.2M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$3.15M -$8.33M -161% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q3 2023 $30.1M $8.14M +$9.66M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $20.4M -$17.6M -$28.9M -255% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $49.3M $5.18M +$3.21M +163% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $46.1M $34.3M +$28.2M +463% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-09
Q3 2022 $17.9M -$1.52M -$34.1M -105% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $52M $11.3M -$22.8M -66.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $74.8M $1.97M -$11.2M -85.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $86M $6.1M -$36.9M -85.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $123M $32.6M -$23.5M -41.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $146M $34.1M -$11.4M -25.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $158M $13.2M -$15.8M -54.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $174M $43M +$2.18M +5.35% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-09
Q3 2020 $172M $56.1M +$16.4M +41.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $155M $45.5M +$2.95M +6.93% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $152M $29M +$3.58M +14.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $149M $40.8M +$961K +2.41% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-28
Q3 2019 $148M $39.7M +$2.25M +6.02% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $145M $42.6M +$6.88M +19.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-17
Q1 2019 $138M $25.4M -$5.97M -19% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $144M $39.9M +$5.51M +16% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $139M $37.5M +$15.1M +67.7% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-28
Q2 2018 $124M $35.7M +$9.65M +37% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-28
Q1 2018 $114M $31.4M +$14.6M +87% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-28
Q4 2017 $99.5M $34.3M +$18M +111% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 $81.5M $22.3M +$2.5M +12.6% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 $79M $26.1M +$14.4M +124% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 $64.6M $16.8M +$10.4M +161% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 $54.2M $16.3M +$8.42M +107% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 $45.8M $19.8M +$14.8M +290% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 $31M $11.6M +$7.8M +203% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 $23.2M $6.44M +$2.4M +59.6% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 $20.8M $7.88M +$2.76M +53.8% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-01
Q3 2015 $18.1M $5.09M +$5.82M Jul 1, 2015 Sep 30, 2015 10-Q 2017-01-20
Q2 2015 $12.3M $3.84M +$88K +2.34% Apr 1, 2015 Jun 30, 2015 10-Q/A 2017-01-23
Q1 2015 $12.2M $4.03M +$17.5M Jan 1, 2015 Mar 31, 2015 10-Q/A 2017-01-20
Q4 2014 -$5.28M $5.12M +$16.5M Oct 1, 2014 Dec 31, 2014 10-K 2017-03-16
Q3 2014 -$21.8M -$736K +$16.4M +95.7% Jul 1, 2014 Sep 30, 2014 10-Q/A 2017-01-20
Q2 2014 -$38.2M $3.76M +$19.2M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 -$57.4M -$13.4M +$4.49M +25.1% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-06
Q4 2013 -$61.9M -$11.4M +$1.39M +10.9% Oct 1, 2013 Dec 31, 2013 10-K/A 2017-01-20
Q3 2013 -$63.3M -$17.2M -$4.89M -39.7% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-12
Q2 2013 -$58.4M -$15.5M -$6.22M -67.2% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-12
Q1 2013 -$52.2M -$17.9M -$10M -127% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-13
Q4 2012 -$42.2M -$12.7M -$2.5M -24.4% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-12
Q3 2012 -$39.7M -$12.3M -$2.38M -24% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-13
Q2 2012 -$37.3M -$9.26M -$861K -10.3% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 -$36.4M -$7.88M +$1.32M +14.4% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-15
Q4 2011 -$37.8M -$10.2M Oct 1, 2011 Dec 31, 2011 10-K 2014-03-21
Q3 2011 -$9.92M Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-02
Q2 2011 -$8.4M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-13
Q1 2011 -$9.2M Jan 1, 2011 Mar 31, 2011 10-Q 2012-06-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.